FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

vasimgton, B.S. 20045

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden

hours per response:

0.5

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Hasija Amit						2. Issuer Name <b>and</b> Ticker or Trading Symbol Milestone Pharmaceuticals Inc. [ MIST ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  Officer (give title Other (specify			
(Last) (First) (Middle) C/O MILESTONE PHARMACEUTICALS INC. 1111 DR. FREDERIK-PHILIPS BLVD, STE 420					3. Date of Earliest Transaction (Month/Day/Year) 09/09/2019							X Cliffe (give title Office (specify below)  CFO & EVP of Corp. Development				
			H4M 2X6	4. If Amendment, Date of Original Filed					ed (Month/E	Line)  X Form filed by One			led by One R led by More t	e Reporting Person ore than One Reporting		
(City)	(City) (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
1. Title of Security (Instr. 3)  2. Transa Date (Month/D					ction 2A. Deemed Execution Date,			3. Transact Code (In:	4. Securities Acquired (A) pisposed Of (D) (Instr. 3, 4			5. Amount of		. Ownership orm: Direct D) or Indirect ) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)		Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	i(s)		
Employee Stock Option (right to buy)	\$22.45	09/09/2019		A		147,000		(1)	09/09/2029	Common Shares	147,000	\$0.00	147,000	D		

## Explanation of Responses:

1. One-fourth (1/4th) of the shares subject to the option vest on September 9, 2020 and one forty-eighth (1/48th) of the shares subject to the option vest on each one month anniversary thereafter, subject to the Reporting Person continuing to provide service through each such date.

## Remarks:

/s/ Eric Popp, Attorney-in-Fact 09/11/2019

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.